PT  - JOURNAL ARTICLE
AU  - Mor, Orna
AU  - Mandelboim, Michal
AU  - Fleishon, Shay
AU  - Bucris, Efrat
AU  - Bar-Ilan, Dana
AU  - Linial, Michal
AU  - Lustig, Yaniv
AU  - ,
AU  - Mendelson, Ella
AU  - Zuckerman, Neta S.
TI  - The rise and fall of an emerging SARS-CoV-2 variant with the spike protein mutation L452R
AID  - 10.1101/2021.07.03.21259957
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.03.21259957
4099  - http://medrxiv.org/content/early/2021/07/07/2021.07.03.21259957.short
4100  - http://medrxiv.org/content/early/2021/07/07/2021.07.03.21259957.full
AB  - Emerging SARS-CoV-2 variants may threaten global vaccination efforts and awaited reduction in outbreak burden. In this study, we report a novel variant carrying the L452R mutation that emerged from a local B.1.362 lineage, B.1.362+L452R. The L452R mutation is associated with the Delta and Epsilon variants and was shown to cause increased infection and reduction in neutralization in pseudoviruses. Indeed, the B.1.362+L452R variant demonstrated a X4-fold reduction in neutralization capacity of sera from BNT162b2-vaccinated individuals compared to a wild-type strain. The variant infected 270 individuals in Israel between December 2020 and March 2021, until diminishing due to the gain in dominance of the Alpha variant in February 2021. This study demonstrates an independent, local emergence of a variant carrying a critical mutation, L452R, which may have the potential of becoming a variant of concern and emphasizes the importance of routine surveillance and detection of novel variants among efforts undertaken to prevent further disease spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). Patient consent was waived because the study used remains of clinical samples and the analysis used anonymous clinical data. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data has been deposited and available in GISAID